


Exploring **Darbepoetin Alfa** potential versus **Epoetin Beta**



Darbepoetin alfa, the first ESA to offer extended dosing intervals among the erythropoietin molecules.¹

Greater proportion of patients achieve Hb >11 g/dL with darbepoetin alfa.¹



Darbepoetin's extended half-life allows for **less frequent dosing** to both **raise and sustain hemoglobin levels**.²

Change for Better...Change to


Cresp[®]
 Darbepoetin alfa 25/40/60µg

Abbreviations

CKD: Chronic kidney disease; ESA: Erythropoiesis-stimulating agent; Hb: Hemoglobin.

References

1. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: Clinical and pharmacoeconomic considerations. *NDT Plus*. 2009;2(Suppl_1):i9-i17.
2. Agarwal AK. Darbepoetin alfa for anemia in chronic kidney disease. *Expert Rev Clin Pharmacol*. 2008;1(3):369-379.

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-I23-0349

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy's Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy's.